Longitudinal trends in hiv nonoccupational postexposure prophylaxis use at a boston community health center between 1997 and 2013

Journal of Acquired Immune Deficiency Syndromes

Volumn 68, Issue 1, 2015, Pages 97-101

  Jain, Sachin ^a   Oldenburg, Catherine E ^b   Mimiaga, Matthew J ^c   Mayer, Kenneth H ^d,e  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b FENWAY INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Biomedical Prevention; Hiv; NPEP; PEP; Postexposure Prophylaxis

Indexed keywords

ANTIRETROVIRUS AGENT; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; INDINAVIR PLUS RITONAVIR; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RALTEGRAVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; DIARRHEA; DRUG ERUPTION; ELECTRONIC MEDICAL RECORD; HEALTH CENTER; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEN WHO HAVE SEX WITH MEN; NAUSEA; POST EXPOSURE PROPHYLAXIS; RETROSPECTIVE STUDY; RISK REDUCTION; SEXUAL BEHAVIOR; UNITED STATES; UNPROTECTED SEX; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; FEMALE; HIV INFECTIONS; ORGANIZATION AND MANAGEMENT;

ADULT; BOSTON; COMMUNITY HEALTH CENTERS; FEMALE; HIV INFECTIONS; HUMANS; MALE; POST-EXPOSURE PROPHYLAXIS;

EID: 84919372044     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000403     Document Type: Article

References (39)

1. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505
2. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363:2587-2599
3. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367: 399-410
4. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423-434
5. Auvert B, Taljaard D, Lagarde E, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 trial. PLoS Med. 2005;2:e298
6. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomized trial. Lancet. 2007; 369:657-666
7. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007;369:643-656
8. Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006-2009. PLoS One. 2011;6:e17502
9. Smith DK, Grohskopf LA, Black RJ, et al. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the US Department of Health and Human Services. MMWR Recomm Rep. 2005;54:1-19
10. Tsai CC, Follis KE, Sabo A, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl) adenine. Science. 1995; 270:1197-1199
11. Otten RA, Smith DK, Adams DR, et al. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a humanderived retrovirus (human immunodeficiency virus type 2). J Virol. 2000; 74:9771-9775
12. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med. 1997;337:1485-1490
13. CDC. HIV testing, risk behaviors among gay, bisexual, and other men who have sex with men-United States. MMWR Morb Mortal Wkly Rep. 2013;62:958-962
14. Mimiaga MJ, Case P, Johnson CV, et al. Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr. 2009;50:77-83
15. Poynten IM, Jin F, Mao L, et al. Nonoccupational postexposure prophylaxis, subsequent risk behaviour and HIV incidence in a cohort of Australian homosexual men. AIDS. 2009;23:1119-1126
16. Donnell D, Mimiaga MJ, Mayer K, et al. Use of non-occupational postexposure prophylaxis does not lead to an increase in high risk sex behaviors in men who have sex with men participating in the EXPLORE trial. AIDS Behav. 2010;14:1182-1189
17. Mehta SA, Silvera R, Bernstein K, et al. Awareness of post-exposure HIV prophylaxis in high-risk men who have sex with men in New York City. Sex Transm Infect. 2011;87:344-348
18. Fernndez-Balbuena S, Belza MJ, Castilla J, et al; Madrid Rapid HIV Testing Group. Awareness and use of nonoccupational HIV postexposure prophylaxis among people receiving rapid HIV testing in Spain. HIV Med. 2013;14:252-257
19. Joshi M, Basra A, McCormick C, et al. Post-exposure prophylaxis after sexual exposure (PEPSE) awareness in an HIV-positive cohort. Int J STD AIDS. 2014;25:67-69
20. Schechter M, do Lago RF, Mendelsohn AB, et al. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr. 2004;35:519-525
21. Zablotska IB, Prestage G, Holt M, et al. Australian gay men who have taken nonoccupational postexposure prophylaxis for HIV are in need of effective HIV prevention methods. J Acquir Immune Defic Syndr. 2011; 58:424-428
22. Pierce AB, Yohannes K, Guy R, et al. HIV seroconversions among male non-occupational post-exposure prophylaxis service users: a data linkage study. Sex Health. 2011;8:179-183
23. Heuker J, Sonder GJ, Stolte I, et al. High HIV incidence among MSM prescribed postexposure prophylaxis, 2000-2009: indications for ongoing sexual risk behaviour. AIDS. 2012;26:505-512
24. Mayer KH, Mimiaga MJ, Cohen D, et al. Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center. J Acquir Immune Defic Syndr. 2008;47:494-499
25. Tosini W, Muller P, Prazuck T, et al. Tolerability of HIV postexposure prophylaxis with tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation. AIDS. 2010;24:2375-2380
26. Burty C, Prazuck T, Truchetet F, et al. Tolerability of two different combinations of antiretroviral drugs including tenofovir used in occupational and nonoccupational postexposure prophylaxis for HIV. AIDS Patient Care STDS. 2010;24:1-3
27. Mayer KH, Mimiaga MJ, Gelman M, et al. Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence. J Acquir Immune Defic Syndr. 2012;59:354-359
28. McAllister J, Read P, McNulty A, et al. Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence. HIV Med. 2014;15: 13-22
29. Rabaud C, Burty C, Grandidier M, et al. Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and lopinavir-ritonavir for HIV infection. Clin Infect Dis. 2005;40: 303-305
30. Burty C, Pavel S, Ghomari K, et al. Tolerability of fosamprenavir/ritonavir associated with zidovudine-lamivudine used as postexposure prophylaxis for HIV infection. J Acquir Immune Defic Syndr. 2008;49:334-336
31. Diaz-Brito V, Len A, Knobel H, et al. Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine. Antivir Ther. 2012;17: 337-346
32. Armishaw J, Hoy JF, Watson KM, et al. Non-occupational post-exposure prophylaxis in Victoria, Australia: responding to high rates of representation and low rates of follow-up. Int J STD AIDS. 2011;22: 714-718
33. McDougal SJ, Alexander J, Dhanireddy S, et al. Non-occupational postexposure prophylaxis for HIV: 10-year retrospective analysis in Seattle, Washington. PLoS One. 2014;9:e105030
34. Rodriguez AE, Castel AD, Parish CL, et al. HIV medical providers perceptions of the use of antiretroviral therapy as nonoccupational postexposure prophylaxis in 2 major metropolitan areas. J Acquir Immune Defic Syndr. 2013;64(suppl 1):S68-S79
35. Martin JN, Roland ME, Neilands TB, et al. Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. AIDS. 2004;18:787-792
36. Sonder GJ, van den Hoek A, Regez RM, et al. Trends in HIV postexposure prophylaxis prescription and compliance after sexual exposure in Amsterdam 2000-2004. Sex Transm Dis. 2007;34:288-293
37. Roland ME, Neilands TB, Krone MR, et al. A randomized noninferiority trial of standard versus enhanced risk reduction and adherence counseling for individuals receiving post-exposure prophylaxis following sexual exposures to HIV. Clin Infect Dis. 2011;53:76-83
38. U.S. Food and Drug Administration. FDA approves first medication to reduce HIV risk. 2012, Available at: http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm311821.htm. Accessed August 28, 2014
39. Bassett IV, Freedberg KA, Walensky RP. Two drugs or three? Balancing efficacy, toxicity, and resistance in postexposure prophylaxis for occupational exposure to HIV. Clin Infect Dis. 2004;39:395-401.